Abiraterone Mylan Ευρωπαϊκή Ένωση - Πορτογαλικά - EMA (European Medicines Agency)

abiraterone mylan

mylan ireland limited - acetato de abiraterona - neoplasias prostáticas - endocrine therapy, other hormone antagonists and related agents - abiraterone mylan is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt). the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated. the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.

Lunsumio Ευρωπαϊκή Ένωση - Πορτογαλικά - EMA (European Medicines Agency)

lunsumio

roche registration gmbh - mosunetuzumab - linfoma, folicular - antineoplastic agents, monoclonal antibodies - lunsumio as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (fl) who have received at least two prior systemic therapies.

Enjaymo Ευρωπαϊκή Ένωση - Πορτογαλικά - EMA (European Medicines Agency)

enjaymo

sanofi b.v. - sutimlimab - hemolysis; anemia, hemolytic, autoimmune - imunossupressores - enjaymo is indicated for the treatment of haemolytic anaemia in adult patients with cold agglutinin disease (cad).

Tecvayli Ευρωπαϊκή Ένωση - Πορτογαλικά - EMA (European Medicines Agency)

tecvayli

janssen-cilag international n.v. - teclistamab - mieloma múltiplo - agentes antineoplásicos - tecvayli is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Amvuttra Ευρωπαϊκή Ένωση - Πορτογαλικά - EMA (European Medicines Agency)

amvuttra

alnylam netherlands b.v. - vutrisiran sodium - amyloid neuropathies, familial - outros medicamentos do sistema nervoso - treatment of hereditary transthyretin-mediated amyloidosis (hattr amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.

Amoxicilina + Ácido Clavulânico Centrient 875 mg + 125 mg Comprimido revestido por película Πορτογαλία - Πορτογαλικά - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

amoxicilina + ácido clavulânico centrient 875 mg + 125 mg comprimido revestido por película

centrient pharmaceuticals netherlands b.v. - amoxicilina + Ácido clavulânico - comprimido revestido por película - 875 mg + 125 mg - amoxicilina tri-hidratada 1004.4 mg ; clavulanato de potássio, diluído com celulose microcristalina (1:1) 297.81 mg - amoxicillin and beta-lactamase inhibitor - genérico - duração do tratamento: curta ou média duração

Amoxicilina + Ácido Clavulânico Centrient 875 mg + 125 mg Comprimido revestido por película Πορτογαλία - Πορτογαλικά - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

amoxicilina + ácido clavulânico centrient 875 mg + 125 mg comprimido revestido por película

centrient pharmaceuticals netherlands b.v. - amoxicilina + Ácido clavulânico - comprimido revestido por película - 875 mg + 125 mg - amoxicilina tri-hidratada 1004.4 mg ; clavulanato de potássio, diluído com celulose microcristalina (1:1) 297.81 mg - amoxicillin and beta-lactamase inhibitor - genérico - duração do tratamento: curta ou média duração

Columvi Ευρωπαϊκή Ένωση - Πορτογαλικά - EMA (European Medicines Agency)

columvi

roche registration gmbh  - glofitamab - lymphoma, large b-cell, diffuse - agentes antineoplásicos - columvi as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl), after two or more lines of systemic therapy.

Degarelix Accord Ευρωπαϊκή Ένωση - Πορτογαλικά - EMA (European Medicines Agency)

degarelix accord

accord healthcare s.l.u. - degarelix acetate - neoplasias prostáticas - other hormone antagonists and related agents - degarelix accord is a gonadotrophin releasing hormone (gnrh) antagonist indicated:for treatment of adult male patients with advanced hormone-dependent prostate cancer. for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.

PREDSIM Βραζιλία - Πορτογαλικά - ANVISA (Agência Nacional de Vigilância Sanitária)

predsim

cosmed industria de cosmeticos e medicamentos s.a. - fosfato sÓdico de prednisolona, prednisolona - glicocorticoides sistemicos